Karalis DG, et al. - Researchers sought to determine differences among eligible patients who were prescribed vs those who were not prescribed a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, in the presence of atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In this retrospective study, it was demonstrated that most PCSK9 inhibitor-eligible patients did not receive a PCSK9 inhibitor prescription. This finding highlights that many high-risk patients could benefit from additional low-density lipoprotein cholesterol-lowering with a PCSK9 inhibitor.